GSK preps for vaccine R&D expansion, 200 hires for new global hub
A year and a half after GlaxoSmithKline set in motion its big flip with Novartis, trading cancer drugs for vaccines, the UK pharma giant has followed through on plans to create a global vaccine R&D center in Rockville, MD, well within the orbit of the NIH and FDA regulators.
This new facility comes with the latest in vaccine tech, says GSK, and will house up to 450 scientists when it’s fully operational. Getting there will take another $50 million investment over the next two years, along with some 200 new hires.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.